Potential of natural products in combination with arsenic trioxide: Investigating cardioprotective effects and mechanisms.
Biomed Pharmacother
; 162: 114464, 2023 Jun.
Article
em En
| MEDLINE
| ID: mdl-37060657
ABSTRACT
Over the past few decades, clinical trials conducted worldwide have demonstrated the efficacy of arsenic trioxide (ATO) in the treatment of relapsed acute promyelocytic leukemia (APL). Currently, ATO has become the frontline treatments for patients with APL. However, its therapeutic applicability is severely constrained by ATO-induced cardiac side effects. Any cardioprotective agents that can ameliorate the cardiac side effects and allow exploiting the full therapeutic potential of ATO, undoubtedly gain significant attention. The knowledge and use of natural products for evidence-based therapy have grown rapidly in recent years. Here we discussed the potential mechanism of ATO-induced cardiac side effects and reviewed the studies on cardiac side effects as well as the research history of ATO in the treatment of APL. Then, We summarized the protective effects and underlying mechanisms of natural products in the treatment of ATO-induced cardiac side effects. Based on the efficacy and safety of the natural product, it has a promising future in the development of cardioprotective agents against ATO-induced cardiac side effects.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Arsenicais
/
Produtos Biológicos
/
Leucemia Promielocítica Aguda
/
Antineoplásicos
Limite:
Humans
Idioma:
En
Revista:
Biomed Pharmacother
Ano de publicação:
2023
Tipo de documento:
Article
País de afiliação:
China